The Order Book

Cognizant re-accelerated from a flat 2023 to +6.9% revenue growth in 2025, its best year since 2016, and enters 2026 with a fuller order book — first-quarter bookings up 21% and a 1.4x book-to-bill [1]. But the coincident line is softening: organic constant-currency growth slipped to roughly 2.9% in Q1 2026, annual contract value went flat, and management now leans on a second-half discretionary recovery it cannot yet see [2]. The leading indicators point up; the near-term ones point down.

The 2025 reacceleration was real — and roughly a third bought

The starting point matters. Revenue was essentially flat in 2023 (‑0.4%) and grew only ~2% in 2024 before jumping 6.9% to $21.1 billion in 2025 [3][4]. That is a genuine inflection: four straight quarters of adjusted-margin expansion, +11% adjusted EPS, and management declaring it had reached its self-set "winner's circle" of large-cap growth two years early [5].

Reported (as-stated) revenue growth. 2022 +5.0% and 2023 −0.4% per the FY2022/FY2024 10-Ks; 2024 +2.0% and 2025 +6.9% per the FY2024/FY2025 10-K MD&A [6][7][8].

The reacceleration was partly purchased. Of the 6.4% constant-currency growth in 2025, about 260 basis points came from the Belcan acquisition, leaving organic constant-currency growth of roughly 3.8% [9]. Through the first half of 2025 the headline looked far stronger — +8.2% constant currency in Q1 and +7.2% in Q2 — but each of those quarters carried ~400 basis points of inorganic Belcan contribution [10][11]. Stripping the acquisition out, the underlying pace was steadier — around 3–4% — not the accelerating curve the reported numbers implied.

The deceleration hides under a lapping acquisition

Because Belcan closed in August 2024, its contribution fades out of the year-over-year math from Q3 2025. That mechanical lapping makes the total constant-currency line look like a collapse — from 8.2% to 3.8% in four quarters — when most of the drop is simply the acquisition anniversarying out. The signal worth watching is the organic line underneath it.

Total constant-currency growth as reported each quarter; organic derived by removing management-stated inorganic contribution (~400bps Q1–Q2, <250bps Q3, nil Q4 all-organic, ~100bps Q1'26 from 3Cloud). Q1'25 organic "4%" and Q4'25 "all organic" are management figures; Q2/Q3/Q1'26 organic are approximate [12][13][14][15][16][17].

Organically, the story is a modest cooling rather than a break. Growth held near 4% through most of 2025 — Q3 marked all four segments growing organically, the strongest sequential organic growth since 2022 [18] — then eased to roughly 2.9% in Q1 2026 (3.9% constant currency less ~100 basis points from the 3Cloud deal) [19]. Management named the cause directly: a "softening demand environment" that has grown "more complex since the start of the year," with the impact of macro uncertainty expected to persist near term [20]. The softness is not new — the company flagged a sharp change in the environment as early as April 2025, when clients in Health Sciences and Products & Resources slowed decision-making [21].

Q1 2026: a strong order book over a soft demand base

The most recent print is a study in mixed signals.

The order book is filling. Q1 2026 bookings grew 21% year-over-year — the strongest in recent history — with 7 large deals of $100 million-plus total contract value, including one mega-deal above $500 million; the trailing-twelve-month book-to-bill rose to 1.4x [22][23]. That extends a pattern: bookings are lumpy quarter to quarter — up 18% in Q2 2025, then down 5% in Q3 — but the trailing trend turned up, from ~5% through 2025 to 11% on a trailing basis in Q1 2026 [24][25][26].

But the quality of that book has shifted. Annual contract value was flat in Q1 2026 even as total contract value surged, because deal duration lengthened — the growth is concentrated in long-dated, cost-takeout and vendor-consolidation megadeals, while "smaller discretionary projects" stayed soft [27]. A fatter book of longer, cheaper-per-year cost-savings work converts to revenue more slowly and at tighter margins than a book of discretionary transformation spend. That is visible already: Q1 gross margin fell 80 basis points year-over-year, and adjusted operating margin expanded only 10 basis points [28].

Segment optics are being distorted by a low-margin pass-through. Cognizant's "integrated offering" strategy resells third-party software products alongside its services, and the swings are large enough to mislead. In Q1 2026 that resale added roughly 10 percentage points of growth to the Communications, Media & Technology segment while subtracting about 300 basis points from Health Sciences; excluding it, Health Sciences services grew in line with the company [29]. The genuine bright spot is Financial Services, up more than 10% in constant currency on healthy discretionary spending across banking and insurance — a real signal, not an accounting one [30].

The guidance architecture: margin raised, revenue held, recovery assumed

How management built the 2026 outlook shows where the risk sits.

FY2026 guidance as issued 4 Feb 2026 and revised 29 Apr 2026. Feb figures from the Q4 2025 guidance supplement; April revisions from the Q1 2026 call [31][32].

Three things stand out. First, the revenue range implies organic constant-currency growth of only about 3.8% at the midpoint — roughly the 2025 organic pace, not an acceleration — with about 150 basis points of the reported growth coming from acquisitions, a third of which is M&A not yet done [33]. Second, the midpoint now assumes a second-half improvement in discretionary spending — a recovery that has not yet appeared in the coincident data [34]. Third, management held revenue but raised adjusted margin and EPS — and the fuel is cost, not volume. The Project LEAP program is guided to deliver $200–300 million of 2026 savings, at a one-time charge of $230–320 million (mostly severance) that is adjusted out of the non-GAAP numbers investors are being asked to value on [35]. Free-cash-flow conversion guidance of 90–100% of net income was unchanged, so the cash engine that anchors the Margin of Safety case is not, on management's own numbers, cracking yet [36].

The read, and what would change it

On the evidence, this is deceleration inside a durable business, not the start of secular decline. Organic growth has cooled from ~4% to ~3%, but it is positive; the book-to-bill at 1.4x and 21% bookings growth say the pipeline is converting; and cash conversion guidance is intact. The honest counter-fact is that the composition has degraded exactly where a skeptic would look: the incremental book is long-dated cost-takeout work with flat ACV and thinner gross margin, the reported EPS beat is manufactured by an adjusted-out restructuring charge, and the full-year revenue midpoint rests on a discretionary recovery management concedes it cannot yet see. The bull and bear can each read this print as confirmation — which is precisely why the next few quarters, not this one, will show which reading holds.

Three observables resolve the direction:

• Organic constant-currency growth. Holding ~3% or reaccelerating toward 4% keeps the FCF base intact; a slide toward 1–2% is the early tell that the model is de-rating on fundamentals, not just multiple.
• Annual contract value, not just TCV. ACV turning positive would signal discretionary demand returning and the book converting to near-term revenue; a second and third flat-ACV quarter says the growth is increasingly deferred, low-margin cost work.
• Margin ex-LEAP and the second-half revenue shape. If the promised H2 discretionary recovery shows up, guidance is conservative; if it does not and margins hold only because LEAP severance keeps being adjusted out, the quality of the beat is the story.